反馈留言



题名	Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta 3/SRC pathway
作者	Zhang, Wenyi1,2; Pan, Rulu1; Lu, Mei1; Zhang, Qian1; Lin, Ziqi1; Qin, Yuan1; Wang, Zhanyu1; Gong, Siqing1; Lin, Huan1; Chong, Shuyi1; Lu, Liting1; Liao, Wanqin3; Lu, Xincheng1
发表日期	2021-11-11
发表期刊	ONCOGENE   影响因子和分区
语种	英语
原始文献类型	Article
其他关键词	THYMIDYLATE SYNTHASE ; DRUG-RESISTANCE ; SRC ACTIVATION ; C-SRC ; CELLS ; PROGRESSION ; SUPPRESSES ; MECHANISM ; BCL-X(L) ; PROTEIN
摘要	The therapeutic efficacy of 5-fluorouracil (5-FU) is often reduced by the development of drug resistance. We observed significant upregulation of lipocalin 2 (LCN2) expression in a newly established 5-FU-resistant colorectal cancer (CRC) cell line. In this study, we demonstrated that 5-FU-treated CRC cells developed resistance through LCN2 upregulation caused by LCN2 promoter demethylation and that feedback between LCN2 and NF-kappa B further amplified LCN2 expression. High LCN2 expression was associated with poor prognosis in CRC patients. LCN2 attenuated the cytotoxicity of 5-FU by activating the SRC/AKT/ERK-mediated antiapoptotic program. Mechanistically, the LCN2-integrin beta 3 interaction enhanced integrin beta 3 stability, thus recruiting SRC to the cytomembrane for autoactivation, leading to downstream AKT/ERK cascade activation. Targeting LCN2 or SRC compromised the growth of CRC cells with LCN2-induced 5-FU resistance. Our findings demonstrate a novel mechanism of acquired resistance to 5-FU, suggesting that LCN2 can be used as a biomarker and/or therapeutic target for advanced CRC.
资助项目	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81972765, 81772966]; Zhejiang Provincial Natural Science FoundationNatural Science Foundation of Zhejiang Province [LZ21H160007]
出版者	SPRINGERNATURE
出版地	LONDON
ISSN	0950-9232
EISSN	1476-5594
卷号	40期号:45页码:6369-6380
DOI	10.1038/s41388-021-02029-4
页数	12
WOS类目	Biochemistry & Molecular Biology ; Oncology ; Cell Biology ; Genetics & Heredity
WOS研究方向	Biochemistry & Molecular Biology ; Oncology ; Cell Biology ; Genetics & Heredity
WOS记录号	WOS:000701380400002
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	34588619
SCOPUSEID	2-s2.0-85116050786
自科自定义期刊分类	T3(B)类
通讯作者地址	[Lu, Xincheng]School of Basic Medical Sciences,Wenzhou Medical University,Wenzhou,325035,China
Scopus学科分类	Molecular Biology;Genetics;Cancer Research
引用统计	被引频次：5[WOS]   [WOS记录]     [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/16999
专题	基础医学院（机能实验教学中心） 附属第一医院_放化疗科
通讯作者	Lu, Xincheng
作者单位	1.School of Basic Medical Sciences,Wenzhou Medical University,Wenzhou,325035,China; 2.Department of Radiotherapy,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 3.Department of Basic Medicine and Biomedical Engineering,Foshan University,Foshan,528200,China
第一作者单位	基础医学院（机能实验教学中心）;  附属第一医院;  第一临床医学院（信息与工程学院）、附属第一医院
通讯作者单位	基础医学院（机能实验教学中心）
第一作者的第一单位	基础医学院（机能实验教学中心）
推荐引用方式 GB/T 7714	Zhang, Wenyi,Pan, Rulu,Lu, Mei,et al. Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta 3/SRC pathway[J]. ONCOGENE,2021,40(45):6369-6380.
APA	Zhang, Wenyi., Pan, Rulu., Lu, Mei., Zhang, Qian., Lin, Ziqi., ... & Lu, Xincheng. (2021). Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta 3/SRC pathway. ONCOGENE, 40(45), 6369-6380.
MLA	Zhang, Wenyi,et al."Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta 3/SRC pathway".ONCOGENE 40.45(2021):6369-6380.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2021-Epigenetic indu（4818KB）	期刊论文	作者接受稿	开放获取	CC BY-NC-SA	浏览 下载

个性服务

查看访问统计

谷歌学术

谷歌学术中相似的文章

[Zhang, Wenyi]的文章

[Pan, Rulu]的文章

[Lu, Mei]的文章

百度学术

百度学术中相似的文章

[Zhang, Wenyi]的文章

[Pan, Rulu]的文章

[Lu, Mei]的文章

必应学术

必应学术中相似的文章

[Zhang, Wenyi]的文章

[Pan, Rulu]的文章

[Lu, Mei]的文章

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。